Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer
2027. márc. 1.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
2027. jan. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Assessment of genomic instability and homologous recombination repair in ovarian cancer using the Oncomine Comprehensive Assay Plus.
2026. nov. 5.· Oncotarget· PUBMED
Publikáció
Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study.
2026. nov. 3.· JCO precision oncology· PUBMED
Publikáció
Impact of BRCA2, BRCA1, and Other Individual Homologous Recombination Repair Alterations on Survival in Metastatic Castration-resistant Prostate Cancer.
2026. nov. 3.· European urology oncology· PUBMED
Vizsgálat
First-in-Human, Multicenter, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of YL-18319 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumors
2026. okt. 30.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
The effect of germline mutations on survival outcomes of breast cancer - Study from a tertiary care center in North India.
2026. okt. 29.· Journal of cancer research and therapeutics· PUBMED
Publikáció
Germline BRCA-Lynch syndrome MINAS: report of six Argentinian families and a systematic review of the literature.
2026. okt. 28.· Familial cancer· PUBMED
Publikáció
BRCA1 Mutation-Recognizing Tetrahedral Framework Nucleic Acid Nanoplatform Enables Coordinated PARP/WEE1 Inhibition and STING-Associated Antitumor Immunity in Ovarian Cancer.
2026. okt. 28.· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publikáció
Multi-omics analysis of high-grade serous ovarian cancers reveals heterogeneity and distinct immunological patterns based upon clinico-genomic status.
2026. okt. 22.· PLoS genetics· PUBMED
Publikáció
Correlation between BRCA mutational status and lymph node metastasis in advanced epithelial ovarian cancer: a retrospective study.
2026. okt. 20.· PeerJ· PUBMED
Publikáció
BRCA1 Promoter Methylation Marks a Shared Blood Methylome State in Women with and Without Breast Cancer.
2026. okt. 19.· International journal of molecular sciences· PUBMED
Publikáció
Occult serous tubal intraepithelial carcinoma and high-grade serous carcinoma at risk-reducing salpingo-oophorectomy in BRCA1/2 carriers: A Czech two-center cohort.
2026. okt. 19.· International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics· PUBMED
Publikáció
Cancer risks associated with BRCA1 and BRCA2: Overview and management.
2026. okt. 15.· Cancer· PUBMED
Publikáció
A urothelial cell carcinoma in the abdominal cavity after salpingectomy for tubo-ovarian carcinoma risk reduction in a BRCA1 pathogenic variant carrier.
2026. okt. 14.· Gynecologic oncology reports· PUBMED
Publikáció
Large-scale integration of functional assay data for the resolution of germline BRCA1 and BRCA2 variants of uncertain significance.
2026. okt. 12.· American journal of human genetics· PUBMED
Publikáció
Somatic panel testing reveals no common alternative oncogenic driver in BRCA1/2-mutant high-grade serous ovarian cancer with discordant low genomic instability score.
2026. okt. 8.· Journal of medical genetics· PUBMED
Publikáció
Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study.
2026. okt. 8.· Nature communications· PUBMED
Publikáció
Case Report: Coexpression of somatic EGFR, BRCA1, and BRCA2 mutations in metastatic non-small cell lung cancer.
2026. okt. 8.· Frontiers in oncology· PUBMED
Publikáció
Re: Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Five-year Results of the IMPACT Study.
2026. okt. 6.· European urology· PUBMED
Vizsgálat
Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants
2026. okt. 1.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
BRCA1/2 Carriers With Breast-Ovarian Double Primary Cancers Versus Ovarian Cancer Alone: Mutation Profiles and Survival Outcomes.
2026. okt. 1.· International journal of cancer· PUBMED
Publikáció
Survival After Risk-Reducing Mastectomy in Patients With Pathogenic Variants in BRCA1 and BRCA2: A Network Meta-Analysis.
2026. okt. 1.· JAMA network open· PUBMED
Publikáció
Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer.
2026. okt. 1.· Cancer research communications· PUBMED
Publikáció
Radiogenomic Analysis of Contrast-Enhanced MRI for Predicting Pathogenic BRCA Variants in Ovarian Cancer.
2026. okt. 1.· Acta medica Okayama· PUBMED
Publikáció
Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions.
2026. okt. 1.· The Journal of clinical investigation· PUBMED
Preprint
Cell-of-origin shapes tumor subtype in BRCA1 -associated triple-negative breast cancer.
2026. szept. 30.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
Clinical implications of the type and genomic location of pathogenic BRCA1 and BRCA2 variants in hereditary breast and ovarian cancer.
2026. szept. 29.· Critical reviews in oncology/hematology· PUBMED
Publikáció
Risk-reducing salpingo-oophorectomy in patients with gBRCA-mutated breast cancer.
2026. szept. 28.· Archives of gynecology and obstetrics· PUBMED
Publikáció
Clinical impact of ENIGMA-based variant reclassification on genotype-phenotype analyses in BRCA1- and BRCA2-associated hereditary breast and ovarian cancer.
2026. szept. 25.· Breast cancer (Tokyo, Japan)· PUBMED